http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0124420-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116c851e729089df9a427027272fa290 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-595 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-595 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 |
| filingDate | 1984-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8cd7fef033fc1a6f43886b9063a56cb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6f473d4549c6b3e7b1c20c212f5f27c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdba009877bd6ce396ba6ff7b44dbb53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53ef98a60e5302c9e1b8aa683219721a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89fb6df361560fc4560bcda1b9f06004 |
| publicationDate | 1984-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0124420-A2 |
| titleOfInvention | Gastric secretion inhibiting peptide derivatives, process for their preparation and medicines containing them |
| abstract | - Asp NH 2 représente l'amide en α de l'acide aspartique de formule:n - R représente l'hydrogène, un groupe protecteur de la fonction amine terminale tel que t.butyloxy carbonyl (BOC), benzyloxy carbonyl (Z), alcanoyle inférieur - A désignen - soit la tyrosine, la tyrosine-O-sulfate, la thréonine ou la méthionine; - soit un dipeptide choisi parmi: -Ala-TYR-, -TYR-Thr-, TYR-Met-, en désignant par TYR l'ensemble des 2 amino-acides constitué par la tyrosine ou la tyrosine-O-sulfate; -- soit un tripeptide choisi parmi: -Glu-Ala-TYR-, -Asp--TYR-Thr-, -Asp-TYR-Met-; - soit un tétrapeptide choisi parmi:.-Glu-Glu-Ala-TYR-, Gln-Asp-TYR-Thr-, -Arg-Asp-TYR-Met-; - soit un pentapeptide choisi parmi: -Glu-Glu-Glu-Ala--TYR-, -Pyr-Gln-Asp-TYR-Thr-, -Asp-Arg-Asp-TYR--Met-. - B désigne la méthionine, la leucine ou la norleucine. The invention relates to peptides of general formula in which - Asp NH 2 represents the amide in α of the aspartic acid of formula: - R represents hydrogen, a protecting group for the terminal amine function such as t.butyloxy carbonyl (BOC), benzyloxy carbonyl (Z), lower alkanoyl - A denotes - either tyrosine, tyrosine-O-sulfate, threonine or methionine; - Or a dipeptide chosen from: -Ala-TYR-, -TYR-Thr-, TYR-Met-, designating by TYR the set of 2 amino acids consisting of tyrosine or tyrosine-O-sulfate; - or a tripeptide chosen from: -Glu-Ala-TYR-, -Asp - TYR-Thr-, -Asp-TYR-Met-; - or a tetrapeptide chosen from: .- Glu-Glu-Ala-TYR-, Gln-Asp-TYR-Thr-, -Arg-Asp-TYR-Met-; - Or a pentapeptide chosen from: -Glu-Glu-Glu-Ala - TYR-, -Pyr-Gln-Asp-TYR-Thr-, -Asp-Arg-Asp-TYR - Met-. - B denotes methionine, leucine or norleucine. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4636490-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0268297-A2 |
| priorityDate | 1983-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 69.